[Immunotherapy advances for lung cancer combined with chronic obstructive pulmonary disease]

Zhonghua Jie He He Hu Xi Za Zhi. 2024 Jan 12;47(1):70-74. doi: 10.3760/cma.j.cn112147-20230905-00142.
[Article in Chinese]

Abstract

Lung cancer is a major public health problem worldwide, with high rates of morbidity and mortality. It often coexists with chronic obstructive pulmonary disease (COPD), the diagnosis and management of which often receives insufficient attention. In particular, the presence of COPD has significant implications for the clinical management of lung cancer patients. This review systematically assesses the influence of COPD on the efficacy of immunotherapy and the occurrence of immune-related adverse events in patients with lung cancer, identifies existing challenges and proposes avenues for future research in this field.

肺癌的发病率和病死率高,在全球范围均是严重的公众健康问题。肺癌患者常合并慢性阻塞性肺疾病(简称慢阻肺),但临床上往往会忽视对肺癌患者合并的慢阻肺的诊断和管理。慢阻肺的存在与否对肺癌患者的临床管理和决策有着重要的意义。本文主要针对合并慢阻肺对肺癌患者免疫治疗疗效和免疫相关不良反应发生情况的影响,以及这一领域目前存在的问题和未来有潜力的研究方向进行综述和探索。.

Publication types

  • Review
  • English Abstract

MeSH terms

  • Humans
  • Immunotherapy
  • Lung Neoplasms* / complications
  • Lung Neoplasms* / therapy
  • Pulmonary Disease, Chronic Obstructive* / complications
  • Pulmonary Disease, Chronic Obstructive* / diagnosis
  • Pulmonary Disease, Chronic Obstructive* / therapy